Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 5/20 | 0.45 |
| ▸ | AKR1B1 | P15121 | 3/20 | 0.35 |
| ▸ | KIF11 | P52732 | 4/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.31 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3428145 | 0.87 | NR3C1 (0.61) | NR3C1AKR1B1KIF11 | |
| SCHEMBL6017520 | 0.85 | NR3C1 (0.40) | NR3C1AKR1B1KIF11MAPTAKR1B10 | |
| SCHEMBL3427005 | 0.77 | NR3C1 (0.63) | NR3C1 | |
| SCHEMBL3424774 | 0.76 | NR3C1 (0.45) | NR3C1AKR1B1MAPTAKR1B10AKR1A1 | |
| SCHEMBL3426216 | 0.73 | NR3C1 (0.53) | NR3C1 | |
| SCHEMBL3427586 | 0.72 | NR3C1 (0.73) | NR3C1 | |
| SCHEMBL4456598 | 0.70 | AKR1B1 (0.45) | NR3C1AKR1B1KIF11MAPTAKR1B10 | |
| SCHEMBL3426318 | 0.69 | NR3C1 (0.43) | NR3C1AKR1B1MAPTAKR1B10AKR1A1 | |
| SCHEMBL3426166 | 0.69 | NR3C1 (0.72) | NR3C1 | |
| SCHEMBL13160268 | 0.68 | NR3C1 (0.55) | NR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1727813-A1 | 2-PROPANOL AND 2-PROPYLAMINE DERIVATIVES AND THEIR USE AS GLUCOCORTICOID LIGANDS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2006-12-06 | — | — | EP | claimed |
| WO-2005090336-A1 | 2-PROPANOL AND 2-PROPYLAMINE DERIVATIVES AND THEIR USE AS GLUCOCORTICOID LIGANDS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-09-29 | — | — | WO | claimed |
| US-20050203128-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-09-15 | — | — | US | claimed |
| US-7795272-B2 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICAL, INC. (US) | 2010-09-14 | — | — | US | disclosed |
| US-7795272-B2 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICAL, INC. (US) | 2010-09-14 | — | — | US | disclosed |
| US-7795272-B2 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICAL, INC. (US) | 2010-09-14 | — | — | US | disclosed |
| US-20050203128-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203128-A1 | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof | NR3C1, NR3C2, MC2R | NR3C1 1/4885AKR1B1 289/4885KIF11 3336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.